Studies with “cross‐over”: percentage of total study population receiving ESA during open‐label phase
Study protocol	Study number	Total	Comment
CC2574‐P‐174	60584	93%	Data provided by company
J89‐040	98358	81%	Data provided by company
EPO‐INT‐3/ CC 2574‐P‐034	36274	76%	Data provided by company
H87‐032, 87‐014/OEU‐U20, 87‐015/OEU‐U21	98906	75%	Data provided by company
I88‐037, 87‐016, 87‐017	34917	75%	Data provided by company
I88‐036, 87‐018, 87‐019	70332	74%	Data provided by company
EPO‐INT‐2/ CC 2574‐P‐467	11220	60%	Data provided by company
20000219	53081	59%	Data from clinical study report
980291	35466	48%	Data from clinical study report
MF4321	45434	48%	Data from clinical study report
980291SCH2	26117	40%	Data from clinical study report
EPO‐INT‐76/EPO‐CA‐489	17100	24%	Data provided by company